{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import xml.etree.ElementTree as ET\n",
    "import numpy as np\n",
    "import torch\n",
    "pd.set_option('display.max_columns', None)  # Show all columns\n",
    "pd.set_option('display.max_rows', 10)     # Show all rows\n",
    "pd.set_option('display.max_colwidth', None)  # Show full column width\n",
    "ddi_path = 'data/ddi.csv'\n",
    "db_smiles_path = 'data/db_smiles.csv'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "\"\"\"\n",
    "The data provided by DrugBank is given in the format of XML so we need to first read and parse the .xml file to extract the \n",
    "relevant information to DDI.\n",
    "\"\"\"\n",
    "\n",
    "def process_drugbank_to_dataframe(file_path):\n",
    "    tree = ET.parse(file_path)\n",
    "    root = tree.getroot()\n",
    "    namespace = {'ns': 'http://www.drugbank.ca'}\n",
    "    data = []\n",
    "    for drug in root.findall('ns:drug', namespace):\n",
    "        primary_id = None\n",
    "        for drugbank_id in drug.findall('ns:drugbank-id', namespace):\n",
    "            # We take primary drugbank-id as our 1st Drug ID because it is in the correct format to be mapped to BindingDB\n",
    "            if drugbank_id.attrib.get('primary') == 'true': \n",
    "                primary_id = drugbank_id.text\n",
    "                break\n",
    "\n",
    "        # If no primary ID is found, skip this drug entry\n",
    "        if not primary_id:\n",
    "            continue\n",
    "\n",
    "        # Extract name and description\n",
    "        name = drug.find('ns:name', namespace)\n",
    "        description = drug.find('ns:description', namespace)\n",
    "        primary_name = name.text if name is not None else 'N/A'\n",
    "        primary_description = description.text if description is not None else 'N/A'\n",
    "\n",
    "        # For each drug there is a list of drug-interaction pairings each with different description\n",
    "        interactions = drug.find('ns:drug-interactions', namespace)\n",
    "\n",
    "        # We skip drug entries that have no DDI records\n",
    "        if interactions:\n",
    "            for interaction in interactions.findall('ns:drug-interaction', namespace):\n",
    "                interacting_drug_id = interaction.find('ns:drugbank-id', namespace).text\n",
    "                interacting_drug_name = interaction.find('ns:name', namespace).text\n",
    "                interaction_description = interaction.find('ns:description', namespace).text\n",
    "\n",
    "                data.append({\n",
    "                    'primary_id': primary_id,\n",
    "                    'primary_name': primary_name,\n",
    "                    'primary_description': primary_description,\n",
    "                    'interacting_drug_id': interacting_drug_id,\n",
    "                    'interacting_drug_name': interacting_drug_name,\n",
    "                    'interaction_description': interaction_description\n",
    "                })\n",
    "\n",
    "    df = pd.DataFrame(data)\n",
    "    multi_index_df = df.set_index(['primary_id', 'interacting_drug_id'])\n",
    "\n",
    "    return multi_index_df\n",
    "\n",
    "file_path = 'data/drugbank.xml'\n",
    "ddi = process_drugbank_to_dataframe(file_path)\n",
    "ddi = ddi.reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>primary_description</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1580646</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Lepirudin.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1580647</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB00006</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Bivalirudin.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1580648</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB00009</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Alteplase</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Alteplase.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1580649</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB00013</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Urokinase</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Urokinase.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1580650</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB00015</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Reteplase</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Reteplase.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1581890</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB11679</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Fruquintinib</td>\n",
       "      <td>The metabolism of Fruquintinib can be decreased when combined with Apixaban.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1581891</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB12005</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Nirogacestat</td>\n",
       "      <td>The serum concentration of Apixaban can be increased when it is combined with Nirogacestat.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1581892</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB16200</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Iptacopan</td>\n",
       "      <td>The metabolism of Iptacopan can be decreased when combined with Apixaban.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1581893</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB14713</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Inotersen</td>\n",
       "      <td>The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Apixaban.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1581894</th>\n",
       "      <td>DB06605</td>\n",
       "      <td>DB11995</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].</td>\n",
       "      <td>Avatrombopag</td>\n",
       "      <td>The metabolism of Avatrombopag can be decreased when combined with Apixaban.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1249 rows × 6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        primary_id interacting_drug_id primary_name  \\\n",
       "1580646    DB06605             DB00001     Apixaban   \n",
       "1580647    DB06605             DB00006     Apixaban   \n",
       "1580648    DB06605             DB00009     Apixaban   \n",
       "1580649    DB06605             DB00013     Apixaban   \n",
       "1580650    DB06605             DB00015     Apixaban   \n",
       "...            ...                 ...          ...   \n",
       "1581890    DB06605             DB11679     Apixaban   \n",
       "1581891    DB06605             DB12005     Apixaban   \n",
       "1581892    DB06605             DB16200     Apixaban   \n",
       "1581893    DB06605             DB14713     Apixaban   \n",
       "1581894    DB06605             DB11995     Apixaban   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                    primary_description  \\\n",
       "1580646  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1580647  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1580648  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1580649  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1580650  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "...                                                                                                                                                                                                                                                                                                                                                                 ...   \n",
       "1581890  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1581891  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1581892  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1581893  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "1581894  Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].   \n",
       "\n",
       "        interacting_drug_name  \\\n",
       "1580646             Lepirudin   \n",
       "1580647           Bivalirudin   \n",
       "1580648             Alteplase   \n",
       "1580649             Urokinase   \n",
       "1580650             Reteplase   \n",
       "...                       ...   \n",
       "1581890          Fruquintinib   \n",
       "1581891          Nirogacestat   \n",
       "1581892             Iptacopan   \n",
       "1581893             Inotersen   \n",
       "1581894          Avatrombopag   \n",
       "\n",
       "                                                                                     interaction_description  \n",
       "1580646                                     Apixaban may increase the anticoagulant activities of Lepirudin.  \n",
       "1580647                                   Apixaban may increase the anticoagulant activities of Bivalirudin.  \n",
       "1580648                                     Apixaban may increase the anticoagulant activities of Alteplase.  \n",
       "1580649                                     Apixaban may increase the anticoagulant activities of Urokinase.  \n",
       "1580650                                     Apixaban may increase the anticoagulant activities of Reteplase.  \n",
       "...                                                                                                      ...  \n",
       "1581890                         The metabolism of Fruquintinib can be decreased when combined with Apixaban.  \n",
       "1581891          The serum concentration of Apixaban can be increased when it is combined with Nirogacestat.  \n",
       "1581892                            The metabolism of Iptacopan can be decreased when combined with Apixaban.  \n",
       "1581893  The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Apixaban.  \n",
       "1581894                         The metabolism of Avatrombopag can be decreased when combined with Apixaban.  \n",
       "\n",
       "[1249 rows x 6 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi[(ddi['primary_id'] == ddi.iloc[0]['interacting_drug_id'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_smiles_from_drugbank(file_path):\n",
    "    tree = ET.parse(file_path)\n",
    "    root = tree.getroot()\n",
    "    namespace = {'ns': 'http://www.drugbank.ca'}\n",
    "    data = []\n",
    "    \n",
    "    for drug in root.findall('ns:drug', namespace):\n",
    "        drugbank_id = drug.find('ns:drugbank-id[@primary=\"true\"]', namespace)\n",
    "        if drugbank_id is None:\n",
    "            continue\n",
    "        primary_id = drugbank_id.text\n",
    "        \n",
    "        smiles_element = drug.find('ns:calculated-properties/ns:property[ns:kind=\"SMILES\"]/ns:value', namespace)\n",
    "        smiles = smiles_element.text if smiles_element is not None else 'N/A'\n",
    "        \n",
    "        data.append({\n",
    "            'DrugBank ID': primary_id,\n",
    "            'SMILES': smiles\n",
    "        })\n",
    "    \n",
    "    df = pd.DataFrame(data)\n",
    "    return df\n",
    "\n",
    "file_path = 'data/drugbank.xml'\n",
    "db_smiles = extract_smiles_from_drugbank(file_path)\n",
    "db_smiles = db_smiles.reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "db_smiles.set_index('index')\n",
    "db_smiles.replace('N/A', np.nan, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "index             0\n",
       "DrugBank ID       0\n",
       "SMILES         4656\n",
       "dtype: int64"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "db_smiles.isna().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(16581, 3)"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "db_smiles.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi.to_csv(ddi_path) # Save DDI "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>primary_description</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06605</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Lepirudin.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06695</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</td>\n",
       "      <td>Dabigatran etexilate</td>\n",
       "      <td>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01254</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</td>\n",
       "      <td>Dasatinib</td>\n",
       "      <td>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01609</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</td>\n",
       "      <td>Deferasirox</td>\n",
       "      <td>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01586</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</td>\n",
       "      <td>Ursodeoxycholic acid</td>\n",
       "      <td>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839605</th>\n",
       "      <td>2839605</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13328</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.</td>\n",
       "      <td>Butanilicaine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Butanilicaine.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839606</th>\n",
       "      <td>2839606</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13578</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.</td>\n",
       "      <td>Metabutethamine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Metabutethamine.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839607</th>\n",
       "      <td>2839607</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13683</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.</td>\n",
       "      <td>Quinisocaine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Quinisocaine.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839608</th>\n",
       "      <td>2839608</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB00565</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.</td>\n",
       "      <td>Cisatracurium</td>\n",
       "      <td>Enmetazobactam may increase the neuromuscular blocking activities of Cisatracurium.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839609</th>\n",
       "      <td>2839609</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB17743</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.</td>\n",
       "      <td>Fecal microbiota</td>\n",
       "      <td>The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2839610 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         Unnamed: 0 primary_id interacting_drug_id    primary_name  \\\n",
       "0                 0    DB00001             DB06605       Lepirudin   \n",
       "1                 1    DB00001             DB06695       Lepirudin   \n",
       "2                 2    DB00001             DB01254       Lepirudin   \n",
       "3                 3    DB00001             DB01609       Lepirudin   \n",
       "4                 4    DB00001             DB01586       Lepirudin   \n",
       "...             ...        ...                 ...             ...   \n",
       "2839605     2839605    DB18716             DB13328  Enmetazobactam   \n",
       "2839606     2839606    DB18716             DB13578  Enmetazobactam   \n",
       "2839607     2839607    DB18716             DB13683  Enmetazobactam   \n",
       "2839608     2839608    DB18716             DB00565  Enmetazobactam   \n",
       "2839609     2839609    DB18716             DB17743  Enmetazobactam   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   primary_description  \\\n",
       "0        Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]   \n",
       "1        Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]   \n",
       "2        Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]   \n",
       "3        Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]   \n",
       "4        Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \\r\\n\\r\\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]   \n",
       "...                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ...   \n",
       "2839605                                                                                                                                                                                                                                                                                                                                                                                           Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.   \n",
       "2839606                                                                                                                                                                                                                                                                                                                                                                                           Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.   \n",
       "2839607                                                                                                                                                                                                                                                                                                                                                                                           Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.   \n",
       "2839608                                                                                                                                                                                                                                                                                                                                                                                           Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.   \n",
       "2839609                                                                                                                                                                                                                                                                                                                                                                                           Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor.[A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections.[A263276] \\r\\n\\r\\nThe combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.[L50126] Enmetazobactam is used as cefepime-sparing therapy by preventing its breakdown by ESBL.   \n",
       "\n",
       "        interacting_drug_name  \\\n",
       "0                    Apixaban   \n",
       "1        Dabigatran etexilate   \n",
       "2                   Dasatinib   \n",
       "3                 Deferasirox   \n",
       "4        Ursodeoxycholic acid   \n",
       "...                       ...   \n",
       "2839605         Butanilicaine   \n",
       "2839606       Metabutethamine   \n",
       "2839607          Quinisocaine   \n",
       "2839608         Cisatracurium   \n",
       "2839609      Fecal microbiota   \n",
       "\n",
       "                                                                                                      interaction_description  \n",
       "0                                                            Apixaban may increase the anticoagulant activities of Lepirudin.  \n",
       "1                                                Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.  \n",
       "2                 The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.  \n",
       "3             The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.  \n",
       "4        The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.  \n",
       "...                                                                                                                       ...  \n",
       "2839605        The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Butanilicaine.  \n",
       "2839606      The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Metabutethamine.  \n",
       "2839607         The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Quinisocaine.  \n",
       "2839608                                   Enmetazobactam may increase the neuromuscular blocking activities of Cisatracurium.  \n",
       "2839609           The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.  \n",
       "\n",
       "[2839610 rows x 7 columns]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi = pd.read_csv(ddi_path)\n",
    "ddi"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4532"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(ddi['primary_id'].unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using device: cpu\n"
     ]
    },
    {
     "ename": "NameError",
     "evalue": "name 'ddi' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[31], line 18\u001b[0m\n\u001b[1;32m     16\u001b[0m tokenizer \u001b[38;5;241m=\u001b[39m AutoTokenizer\u001b[38;5;241m.\u001b[39mfrom_pretrained(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdmis-lab/biobert-v1.1\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m     17\u001b[0m model \u001b[38;5;241m=\u001b[39m AutoModel\u001b[38;5;241m.\u001b[39mfrom_pretrained(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdmis-lab/biobert-v1.1\u001b[39m\u001b[38;5;124m\"\u001b[39m)\u001b[38;5;241m.\u001b[39mto(device)\n\u001b[0;32m---> 18\u001b[0m texts \u001b[38;5;241m=\u001b[39m \u001b[43mddi\u001b[49m[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124minteraction_description\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mto_list()\n\u001b[1;32m     19\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mget_embeddings_in_batches\u001b[39m(texts, batch_size\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m32\u001b[39m):\n\u001b[1;32m     20\u001b[0m     embeddings \u001b[38;5;241m=\u001b[39m []\n",
      "\u001b[0;31mNameError\u001b[0m: name 'ddi' is not defined"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7b9a6b701c004f7886d423fff01588f8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "model.safetensors:   0%|          | 0.00/433M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from tqdm import tqdm\n",
    "import torch\n",
    "import numpy as np\n",
    "from transformers import AutoTokenizer, AutoModel\n",
    "from sklearn.cluster import KMeans\n",
    "\n",
    "\"\"\"\n",
    "Experimental approach to cluster the interaction description of DDI.\n",
    "We use BioBert (a pretrained BERT model on biological texts) to extract the context appropriate embeddings for out descriptions.\n",
    "Then we apply K-Means to cluster the embeddings into three clusters which later are interpretated as 'Major', 'Moderate' or 'Minor' \n",
    "sensitivity.\n",
    "\"\"\"\n",
    "\n",
    "device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
    "print(f\"Using device: {device}\")\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"dmis-lab/biobert-v1.1\")\n",
    "model = AutoModel.from_pretrained(\"dmis-lab/biobert-v1.1\").to(device)\n",
    "texts = ddi['interaction_description'].to_list()\n",
    "def get_embeddings_in_batches(texts, batch_size=32):\n",
    "    embeddings = []\n",
    "    # Proceed in batches to minimize time of execution.\n",
    "    for i in tqdm(range(0, len(texts), batch_size), desc=\"Processing batches\"):\n",
    "        batch_texts = texts[i:i+batch_size]\n",
    "        tokens = tokenizer(batch_texts, return_tensors=\"pt\", padding=True, truncation=True, max_length=512).to(device)\n",
    "        with torch.no_grad():\n",
    "            outputs = model(**tokens)\n",
    "        batch_embeddings = outputs.last_hidden_state[:, 0, :].cpu().numpy()\n",
    "        embeddings.append(batch_embeddings)\n",
    "    return np.vstack(embeddings)\n",
    "\n",
    "embeddings = get_embeddings_in_batches(texts, batch_size=32)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "n_clusters = 3 \n",
    "kmeans = KMeans(n_clusters=n_clusters, random_state=42)\n",
    "labels = kmeans.fit_predict(embeddings) # Perform k-means clustering"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "interaction_types = {0: \"major\", 1: \"moderate\", 2: \"minor\"} # Cluster label interpretation map"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi['labels'] = labels\n",
    "ddi['label_meaning'] = [interaction_types[i] for i in labels]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi.to_csv(ddi_path) # Save DDI "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi = pd.read_csv(ddi_path)\n",
    "labels = ddi['labels'].to_list()\n",
    "ddi"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Manually check the correctness of sample's labeling\n",
    "output_file = 'data/interactions.txt'\n",
    "\n",
    "with open(output_file, 'w') as file:\n",
    "    for interaction in ddi[['interaction_description', 'label_meaning']].values[::10000]:\n",
    "        file.write(f\"{interaction[0]} - {interaction[1]}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi_labels = pd.read_csv('data/ddi_with_labels.csv')\n",
    "ddi_labels['label_meaning'] = ddi_labels['labels'].apply(lambda x: interaction_types[x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "      <th>labels</th>\n",
       "      <th>label_meaning</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06605</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06695</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dabigatran etexilate</td>\n",
       "      <td>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01254</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dasatinib</td>\n",
       "      <td>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01609</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Deferasirox</td>\n",
       "      <td>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01586</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Ursodeoxycholic acid</td>\n",
       "      <td>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839605</th>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13328</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Butanilicaine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Butanilicaine.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839606</th>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13578</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Metabutethamine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Metabutethamine.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839607</th>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB13683</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Quinisocaine</td>\n",
       "      <td>The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Quinisocaine.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839608</th>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB00565</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Cisatracurium</td>\n",
       "      <td>Enmetazobactam may increase the neuromuscular blocking activities of Cisatracurium.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2839609</th>\n",
       "      <td>DB18716</td>\n",
       "      <td>DB17743</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>Fecal microbiota</td>\n",
       "      <td>The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.</td>\n",
       "      <td>0</td>\n",
       "      <td>major</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2839610 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        primary_id interacting_drug_id    primary_name interacting_drug_name  \\\n",
       "0          DB00001             DB06605       Lepirudin              Apixaban   \n",
       "1          DB00001             DB06695       Lepirudin  Dabigatran etexilate   \n",
       "2          DB00001             DB01254       Lepirudin             Dasatinib   \n",
       "3          DB00001             DB01609       Lepirudin           Deferasirox   \n",
       "4          DB00001             DB01586       Lepirudin  Ursodeoxycholic acid   \n",
       "...            ...                 ...             ...                   ...   \n",
       "2839605    DB18716             DB13328  Enmetazobactam         Butanilicaine   \n",
       "2839606    DB18716             DB13578  Enmetazobactam       Metabutethamine   \n",
       "2839607    DB18716             DB13683  Enmetazobactam          Quinisocaine   \n",
       "2839608    DB18716             DB00565  Enmetazobactam         Cisatracurium   \n",
       "2839609    DB18716             DB17743  Enmetazobactam      Fecal microbiota   \n",
       "\n",
       "                                                                                                      interaction_description  \\\n",
       "0                                                            Apixaban may increase the anticoagulant activities of Lepirudin.   \n",
       "1                                                Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.   \n",
       "2                 The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.   \n",
       "3             The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.   \n",
       "4        The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.   \n",
       "...                                                                                                                       ...   \n",
       "2839605        The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Butanilicaine.   \n",
       "2839606      The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Metabutethamine.   \n",
       "2839607         The risk or severity of methemoglobinemia can be increased when Enmetazobactam is combined with Quinisocaine.   \n",
       "2839608                                   Enmetazobactam may increase the neuromuscular blocking activities of Cisatracurium.   \n",
       "2839609           The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.   \n",
       "\n",
       "         labels label_meaning  \n",
       "0             2         minor  \n",
       "1             2         minor  \n",
       "2             1      moderate  \n",
       "3             1      moderate  \n",
       "4             1      moderate  \n",
       "...         ...           ...  \n",
       "2839605       1      moderate  \n",
       "2839606       1      moderate  \n",
       "2839607       1      moderate  \n",
       "2839608       2         minor  \n",
       "2839609       0         major  \n",
       "\n",
       "[2839610 rows x 7 columns]"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels.drop(columns=['Unnamed: 0.1', 'Unnamed: 0', 'primary_description'], inplace=True, errors='ignore')\n",
    "ddi_labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Drop duplicated pairs\n",
    "ddi_labels[['primary_id', 'interacting_drug_id']] = ddi_labels.apply(lambda x: sorted([x['primary_id'], x['interacting_drug_id']]), axis=1, result_type='expand')\n",
    "ddi_labels = ddi_labels.drop_duplicates(subset=['primary_id', 'interacting_drug_id'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "      <th>labels</th>\n",
       "      <th>label_meaning</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06605</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06695</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dabigatran etexilate</td>\n",
       "      <td>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01254</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dasatinib</td>\n",
       "      <td>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01609</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Deferasirox</td>\n",
       "      <td>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01586</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Ursodeoxycholic acid</td>\n",
       "      <td>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2837460</th>\n",
       "      <td>DB17472</td>\n",
       "      <td>DB17762</td>\n",
       "      <td>Pirtobrutinib</td>\n",
       "      <td>Respiratory syncytial virus vaccine, adjuvanted</td>\n",
       "      <td>The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Pirtobrutinib.</td>\n",
       "      <td>0</td>\n",
       "      <td>major</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2837468</th>\n",
       "      <td>DB17472</td>\n",
       "      <td>DB18701</td>\n",
       "      <td>Pirtobrutinib</td>\n",
       "      <td>Chikungunya vaccine (live, attenuated)</td>\n",
       "      <td>The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pirtobrutinib.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2837473</th>\n",
       "      <td>DB17472</td>\n",
       "      <td>DB18705</td>\n",
       "      <td>Pirtobrutinib</td>\n",
       "      <td>SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)</td>\n",
       "      <td>The therapeutic efficacy of SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains) can be decreased when used in combination with Pirtobrutinib.</td>\n",
       "      <td>0</td>\n",
       "      <td>major</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2837811</th>\n",
       "      <td>DB17743</td>\n",
       "      <td>DB18716</td>\n",
       "      <td>Fecal microbiota</td>\n",
       "      <td>Enmetazobactam</td>\n",
       "      <td>The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.</td>\n",
       "      <td>0</td>\n",
       "      <td>major</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2838213</th>\n",
       "      <td>DB09368</td>\n",
       "      <td>DB17929</td>\n",
       "      <td>DaxibotulinumtoxinA</td>\n",
       "      <td>Corticotropin zinc hydroxide</td>\n",
       "      <td>The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Corticotropin zinc hydroxide.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1420072 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        primary_id interacting_drug_id         primary_name  \\\n",
       "0          DB00001             DB06605            Lepirudin   \n",
       "1          DB00001             DB06695            Lepirudin   \n",
       "2          DB00001             DB01254            Lepirudin   \n",
       "3          DB00001             DB01609            Lepirudin   \n",
       "4          DB00001             DB01586            Lepirudin   \n",
       "...            ...                 ...                  ...   \n",
       "2837460    DB17472             DB17762        Pirtobrutinib   \n",
       "2837468    DB17472             DB18701        Pirtobrutinib   \n",
       "2837473    DB17472             DB18705        Pirtobrutinib   \n",
       "2837811    DB17743             DB18716     Fecal microbiota   \n",
       "2838213    DB09368             DB17929  DaxibotulinumtoxinA   \n",
       "\n",
       "                                                                                                             interacting_drug_name  \\\n",
       "0                                                                                                                         Apixaban   \n",
       "1                                                                                                             Dabigatran etexilate   \n",
       "2                                                                                                                        Dasatinib   \n",
       "3                                                                                                                      Deferasirox   \n",
       "4                                                                                                             Ursodeoxycholic acid   \n",
       "...                                                                                                                            ...   \n",
       "2837460                                                                            Respiratory syncytial virus vaccine, adjuvanted   \n",
       "2837468                                                                                     Chikungunya vaccine (live, attenuated)   \n",
       "2837473  SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)   \n",
       "2837811                                                                                                             Enmetazobactam   \n",
       "2838213                                                                                               Corticotropin zinc hydroxide   \n",
       "\n",
       "                                                                                                                                                                                                     interaction_description  \\\n",
       "0                                                                                                                                                           Apixaban may increase the anticoagulant activities of Lepirudin.   \n",
       "1                                                                                                                                               Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.   \n",
       "2                                                                                                                The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.   \n",
       "3                                                                                                            The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.   \n",
       "4                                                                                                       The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.   \n",
       "...                                                                                                                                                                                                                      ...   \n",
       "2837460                                                                                                               The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Pirtobrutinib.   \n",
       "2837468                                                                                       The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pirtobrutinib.   \n",
       "2837473  The therapeutic efficacy of SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains) can be decreased when used in combination with Pirtobrutinib.   \n",
       "2837811                                                                                                          The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Enmetazobactam.   \n",
       "2838213                                                                               The risk or severity of myopathy and weakness can be increased when DaxibotulinumtoxinA is combined with Corticotropin zinc hydroxide.   \n",
       "\n",
       "         labels label_meaning  \n",
       "0             2         minor  \n",
       "1             2         minor  \n",
       "2             1      moderate  \n",
       "3             1      moderate  \n",
       "4             1      moderate  \n",
       "...         ...           ...  \n",
       "2837460       0         major  \n",
       "2837468       1      moderate  \n",
       "2837473       0         major  \n",
       "2837811       0         major  \n",
       "2838213       1      moderate  \n",
       "\n",
       "[1420072 rows x 7 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [],
   "source": [
    "db_smiles.rename(columns={'DrugBank ID': 'primary_id', 'SMILES': 'primary_smiles'}, inplace=True)\n",
    "ddi_labels = pd.merge(ddi_labels, db_smiles, how='left', on='primary_id')\n",
    "db_smiles.rename(columns={'primary_id': 'interacting_drug_id', 'primary_smiles': 'interaction_drug_smiles'}, inplace=True)\n",
    "ddi_labels = pd.merge(ddi_labels, db_smiles, how='left', on='interacting_drug_id')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "primary_id                      0\n",
       "interacting_drug_id             0\n",
       "primary_name                    0\n",
       "interacting_drug_name           0\n",
       "interaction_description         0\n",
       "labels                          0\n",
       "label_meaning                   0\n",
       "primary_smiles             146645\n",
       "interaction_drug_smiles    183212\n",
       "dtype: int64"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels.drop(columns=['index_x', 'index_y'], inplace=True, errors='ignore')\n",
    "ddi_labels.isna().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "      <th>labels</th>\n",
       "      <th>label_meaning</th>\n",
       "      <th>primary_smiles</th>\n",
       "      <th>interaction_drug_smiles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06605</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "      <td>NaN</td>\n",
       "      <td>COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB06695</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dabigatran etexilate</td>\n",
       "      <td>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01254</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Dasatinib</td>\n",
       "      <td>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01609</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Deferasirox</td>\n",
       "      <td>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB00001</td>\n",
       "      <td>DB01586</td>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Ursodeoxycholic acid</td>\n",
       "      <td>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>NaN</td>\n",
       "      <td>[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  primary_id interacting_drug_id primary_name interacting_drug_name  \\\n",
       "0    DB00001             DB06605    Lepirudin              Apixaban   \n",
       "1    DB00001             DB06695    Lepirudin  Dabigatran etexilate   \n",
       "2    DB00001             DB01254    Lepirudin             Dasatinib   \n",
       "3    DB00001             DB01609    Lepirudin           Deferasirox   \n",
       "4    DB00001             DB01586    Lepirudin  Ursodeoxycholic acid   \n",
       "\n",
       "                                                                                                interaction_description  \\\n",
       "0                                                      Apixaban may increase the anticoagulant activities of Lepirudin.   \n",
       "1                                          Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.   \n",
       "2           The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.   \n",
       "3       The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.   \n",
       "4  The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.   \n",
       "\n",
       "   labels label_meaning primary_smiles  \\\n",
       "0       2         minor            NaN   \n",
       "1       2         minor            NaN   \n",
       "2       1      moderate            NaN   \n",
       "3       1      moderate            NaN   \n",
       "4       1      moderate            NaN   \n",
       "\n",
       "                                                                                         interaction_drug_smiles  \n",
       "0                                            COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O  \n",
       "1                         CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1  \n",
       "2                                                CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1  \n",
       "3                                                         OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O  \n",
       "4  [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O  "
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi_labels.dropna(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[18:56:54] Unusual charge on atom 0 number of radical electrons set to zero\n",
      "[18:56:54] SMILES Parse Error: syntax error while parsing: OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1\n",
      "[18:56:54] SMILES Parse Error: Failed parsing SMILES 'OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1' for input: 'OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1'\n",
      "[18:56:55] Unusual charge on atom 0 number of radical electrons set to zero\n",
      "[18:56:55] SMILES Parse Error: syntax error while parsing: OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1\n",
      "[18:56:55] SMILES Parse Error: Failed parsing SMILES 'OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1' for input: 'OC1=CC=CC(=C1)C-1=C2\\CCC(=N2)\\C(=C2/N\\C(\\C=C2)=C(/C2=N/C(/C=C2)=C(\\C2=CC=C\\-1N2)C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\\C1=CC(O)=CC=C1'\n"
     ]
    }
   ],
   "source": [
    "from likeness import check_smiles_validity\n",
    "primary_isvalid = check_smiles_validity(ddi_labels['primary_smiles'].unique())\n",
    "interaction_drug_isvalid = check_smiles_validity(ddi_labels['interaction_drug_smiles'].unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "SMILES    1\n",
       "Valid     1\n",
       "dtype: int64"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "primary_isvalid[primary_isvalid['Valid'] != True].count()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "SMILES    1\n",
       "Valid     1\n",
       "dtype: int64"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "interaction_drug_isvalid[interaction_drug_isvalid['Valid'] != True].count()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>primary_id</th>\n",
       "      <th>interacting_drug_id</th>\n",
       "      <th>primary_name</th>\n",
       "      <th>interacting_drug_name</th>\n",
       "      <th>interaction_description</th>\n",
       "      <th>labels</th>\n",
       "      <th>label_meaning</th>\n",
       "      <th>primary_smiles</th>\n",
       "      <th>interaction_drug_smiles</th>\n",
       "      <th>primary_isvalid</th>\n",
       "      <th>interaction_drug_isvalid</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>DB06605</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Apixaban</td>\n",
       "      <td>Apixaban may increase the anticoagulant activities of Bivalirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "      <td>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</td>\n",
       "      <td>COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>DB06695</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Dabigatran etexilate</td>\n",
       "      <td>Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.</td>\n",
       "      <td>2</td>\n",
       "      <td>minor</td>\n",
       "      <td>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</td>\n",
       "      <td>CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>DB01254</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Dasatinib</td>\n",
       "      <td>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bivalirudin.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</td>\n",
       "      <td>CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>DB01609</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Deferasirox</td>\n",
       "      <td>The risk or severity of gastrointestinal bleeding can be increased when Bivalirudin is combined with Deferasirox.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</td>\n",
       "      <td>OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>DB00006</td>\n",
       "      <td>DB01586</td>\n",
       "      <td>Bivalirudin</td>\n",
       "      <td>Ursodeoxycholic acid</td>\n",
       "      <td>The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Ursodeoxycholic acid.</td>\n",
       "      <td>1</td>\n",
       "      <td>moderate</td>\n",
       "      <td>CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O</td>\n",
       "      <td>[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  primary_id interacting_drug_id primary_name interacting_drug_name  \\\n",
       "0    DB00006             DB06605  Bivalirudin              Apixaban   \n",
       "1    DB00006             DB06695  Bivalirudin  Dabigatran etexilate   \n",
       "2    DB00006             DB01254  Bivalirudin             Dasatinib   \n",
       "3    DB00006             DB01609  Bivalirudin           Deferasirox   \n",
       "4    DB00006             DB01586  Bivalirudin  Ursodeoxycholic acid   \n",
       "\n",
       "                                                                                                  interaction_description  \\\n",
       "0                                                      Apixaban may increase the anticoagulant activities of Bivalirudin.   \n",
       "1                                          Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.   \n",
       "2           The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Bivalirudin.   \n",
       "3       The risk or severity of gastrointestinal bleeding can be increased when Bivalirudin is combined with Deferasirox.   \n",
       "4  The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Ursodeoxycholic acid.   \n",
       "\n",
       "   labels label_meaning  \\\n",
       "0       2         minor   \n",
       "1       2         minor   \n",
       "2       1      moderate   \n",
       "3       1      moderate   \n",
       "4       1      moderate   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                          primary_smiles  \\\n",
       "0  CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O   \n",
       "1  CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O   \n",
       "2  CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O   \n",
       "3  CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O   \n",
       "4  CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O   \n",
       "\n",
       "                                                                                         interaction_drug_smiles  \\\n",
       "0                                            COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O   \n",
       "1                         CCCCCCOC(=O)\\N=C(\\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1   \n",
       "2                                                CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1   \n",
       "3                                                         OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O   \n",
       "4  [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O   \n",
       "\n",
       "   primary_isvalid  interaction_drug_isvalid  \n",
       "0             True                      True  \n",
       "1             True                      True  \n",
       "2             True                      True  \n",
       "3             True                      True  \n",
       "4             True                      True  "
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "primary_isvalid.rename(columns={'SMILES': 'primary_smiles', 'Valid': 'primary_isvalid'}, inplace=True)\n",
    "interaction_drug_isvalid.rename(columns={'SMILES': 'interaction_drug_smiles', 'Valid': 'interaction_drug_isvalid'}, inplace=True)\n",
    "ddi_labels = pd.merge(ddi_labels, primary_isvalid, how='left', on='primary_smiles')\n",
    "ddi_labels = pd.merge(ddi_labels, interaction_drug_isvalid, how='left', on='interaction_drug_smiles')\n",
    "ddi_labels.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "primary_id                  37\n",
       "interacting_drug_id         37\n",
       "primary_name                37\n",
       "interacting_drug_name       37\n",
       "interaction_description     37\n",
       "                            ..\n",
       "label_meaning               37\n",
       "primary_smiles              37\n",
       "interaction_drug_smiles     37\n",
       "primary_isvalid             37\n",
       "interaction_drug_isvalid    37\n",
       "Length: 11, dtype: int64"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels[(ddi_labels['primary_isvalid'] != True) | (ddi_labels['interaction_drug_isvalid'] != True)].count()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi_labels = ddi_labels[(ddi_labels['primary_isvalid'] == True) & (ddi_labels['interaction_drug_isvalid'] == True)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(1163415, 11)"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## RD Kit Experiments"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [],
   "source": [
    "from rdkit import Chem\n",
    "from rdkit.Chem import AllChem"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<PIL.PngImagePlugin.PngImageFile image mode=RGB size=300x300>"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "smile = ddi_labels.iloc[0]['interaction_drug_smiles']\n",
    "m = Chem.MolFromSmiles(smile)\n",
    "img = Chem.Draw.MolToImage(m)\n",
    "img"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_fingerprints(smiles_list, prefix):\n",
    "    molecules = [Chem.MolFromSmiles(smile) for smile in smiles_list]\n",
    "    fingerprints = [AllChem.GetMorganFingerprintAsBitVect(mol, radius=2, nBits=2048) for mol in molecules]\n",
    "    fingerprint_arrays = [np.array(fingerprint) for fingerprint in fingerprints]\n",
    "    res_df = pd.DataFrame({\n",
    "        f'{prefix}_smiles': smiles_list,\n",
    "        f'{prefix}_fingerprint': fingerprint_arrays\n",
    "    })\n",
    "    return res_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[18:56:56] Unusual charge on atom 0 number of radical electrons set to zero\n",
      "[18:57:05] Unusual charge on atom 0 number of radical electrons set to zero\n"
     ]
    },
    {
     "ename": "",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31mThe Kernel crashed while executing code in the current cell or a previous cell. \n",
      "\u001b[1;31mPlease review the code in the cell(s) to identify a possible cause of the failure. \n",
      "\u001b[1;31mClick <a href='https://aka.ms/vscodeJupyterKernelCrash'>here</a> for more info. \n",
      "\u001b[1;31mView Jupyter <a href='command:jupyter.viewOutput'>log</a> for further details."
     ]
    }
   ],
   "source": [
    "primary_fingerprint_df = create_fingerprints(ddi_labels['primary_smiles'].unique(), 'primary')\n",
    "interaction_drug_fingerprint_df = create_fingerprints(ddi_labels['interaction_drug_smiles'].unique(), 'interaction_drug')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import ast\n",
    "ddi_labels = pd.merge(ddi_labels, primary_fingerprint_df, how='left', on='primary_smiles')\n",
    "ddi_labels = pd.merge(ddi_labels, interaction_drug_fingerprint_df, how='left', on='interaction_drug_smiles')\n",
    "\n",
    "ddi_labels['concat_fingerprints'] = ddi_labels.apply(\n",
    "    lambda row: np.concatenate([row['primary_fingerprint'], row['interaction_drug_fingerprint']]), axis=1\n",
    ")\n",
    "ddi_labels.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi_labels.to_csv('data/ddi_labels_complete.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "ddi_labels = pd.read_csv('data/ddi_labels_complete.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "from sklearn.ensemble import RandomForestClassifier\n",
    "from sklearn.metrics import classification_report, confusion_matrix\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/9z/jvyz2w6d2v1bbg_kkfnms6m00000gn/T/ipykernel_4373/3279322215.py:9: UserWarning: No artists with labels found to put in legend.  Note that artists whose label start with an underscore are ignored when legend() is called with no argument.\n",
      "  plt.legend()\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "label_counts = ddi_labels['label_meaning'].value_counts()\n",
    "plt.figure(figsize=(12, 6))\n",
    "plt.bar(label_counts.index, label_counts, color='#aad7d4')\n",
    "plt.title('Label Counts', fontsize=16)\n",
    "plt.xlabel('Label', fontsize=12)\n",
    "plt.ylabel('Frequency', fontsize=12)\n",
    "plt.xticks(rotation=45)\n",
    "plt.legend()\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyError",
     "evalue": "'concat_fingerprint'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "File \u001b[0;32m/opt/homebrew/lib/python3.10/site-packages/pandas/core/indexes/base.py:3802\u001b[0m, in \u001b[0;36mIndex.get_loc\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   3801\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m-> 3802\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_engine\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mget_loc\u001b[49m\u001b[43m(\u001b[49m\u001b[43mcasted_key\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   3803\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mKeyError\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m err:\n",
      "File \u001b[0;32mindex.pyx:153\u001b[0m, in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32mindex.pyx:182\u001b[0m, in \u001b[0;36mpandas._libs.index.IndexEngine.get_loc\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32mpandas/_libs/hashtable_class_helper.pxi:7081\u001b[0m, in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "File \u001b[0;32mpandas/_libs/hashtable_class_helper.pxi:7089\u001b[0m, in \u001b[0;36mpandas._libs.hashtable.PyObjectHashTable.get_item\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;31mKeyError\u001b[0m: 'concat_fingerprint'",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[0;31mKeyError\u001b[0m                                  Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[43], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m ddi_labels[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mconcat_fingerprint\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m \u001b[43mddi_labels\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[38;5;124;43mconcat_fingerprint\u001b[39;49m\u001b[38;5;124;43m'\u001b[39;49m\u001b[43m]\u001b[49m\u001b[38;5;241m.\u001b[39mapply(ast\u001b[38;5;241m.\u001b[39mliteral_eval)\n\u001b[1;32m      2\u001b[0m ddi_labels[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mlen_fingerprints\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m ddi_labels[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mconcat_fingerprints\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mapply(\n\u001b[1;32m      3\u001b[0m     \u001b[38;5;28;01mlambda\u001b[39;00m x: \u001b[38;5;28mlen\u001b[39m(x)\n\u001b[1;32m      4\u001b[0m )\n\u001b[1;32m      5\u001b[0m ddi_labels[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mlen_fingerprints\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39munique()\n",
      "File \u001b[0;32m/opt/homebrew/lib/python3.10/site-packages/pandas/core/frame.py:4090\u001b[0m, in \u001b[0;36mDataFrame.__getitem__\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   4088\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mcolumns\u001b[38;5;241m.\u001b[39mnlevels \u001b[38;5;241m>\u001b[39m \u001b[38;5;241m1\u001b[39m:\n\u001b[1;32m   4089\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_getitem_multilevel(key)\n\u001b[0;32m-> 4090\u001b[0m indexer \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mcolumns\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mget_loc\u001b[49m\u001b[43m(\u001b[49m\u001b[43mkey\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   4091\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m is_integer(indexer):\n\u001b[1;32m   4092\u001b[0m     indexer \u001b[38;5;241m=\u001b[39m [indexer]\n",
      "File \u001b[0;32m/opt/homebrew/lib/python3.10/site-packages/pandas/core/indexes/base.py:3809\u001b[0m, in \u001b[0;36mIndex.get_loc\u001b[0;34m(self, key)\u001b[0m\n\u001b[1;32m   3804\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(casted_key, \u001b[38;5;28mslice\u001b[39m) \u001b[38;5;129;01mor\u001b[39;00m (\n\u001b[1;32m   3805\u001b[0m         \u001b[38;5;28misinstance\u001b[39m(casted_key, abc\u001b[38;5;241m.\u001b[39mIterable)\n\u001b[1;32m   3806\u001b[0m         \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28many\u001b[39m(\u001b[38;5;28misinstance\u001b[39m(x, \u001b[38;5;28mslice\u001b[39m) \u001b[38;5;28;01mfor\u001b[39;00m x \u001b[38;5;129;01min\u001b[39;00m casted_key)\n\u001b[1;32m   3807\u001b[0m     ):\n\u001b[1;32m   3808\u001b[0m         \u001b[38;5;28;01mraise\u001b[39;00m InvalidIndexError(key)\n\u001b[0;32m-> 3809\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mKeyError\u001b[39;00m(key) \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01merr\u001b[39;00m\n\u001b[1;32m   3810\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mTypeError\u001b[39;00m:\n\u001b[1;32m   3811\u001b[0m     \u001b[38;5;66;03m# If we have a listlike key, _check_indexing_error will raise\u001b[39;00m\n\u001b[1;32m   3812\u001b[0m     \u001b[38;5;66;03m#  InvalidIndexError. Otherwise we fall through and re-raise\u001b[39;00m\n\u001b[1;32m   3813\u001b[0m     \u001b[38;5;66;03m#  the TypeError.\u001b[39;00m\n\u001b[1;32m   3814\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_check_indexing_error(key)\n",
      "\u001b[0;31mKeyError\u001b[0m: 'concat_fingerprint'"
     ]
    }
   ],
   "source": [
    "ddi_labels['concat_fingerprint'] = ddi_labels['concat_fingerprint'].apply(ast.literal_eval)\n",
    "ddi_labels['len_fingerprints'] = ddi_labels['concat_fingerprints'].apply(\n",
    "    lambda x: len(x)\n",
    ")\n",
    "ddi_labels['len_fingerprints'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'[0 1 0 ... 0 0 0]'"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ddi_labels.iloc[0]['primary_fingerprint']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "ename": "TypeError",
     "evalue": "can't convert np.ndarray of type numpy.str_. The only supported types are: float64, float32, float16, complex64, complex128, int64, int32, int16, int8, uint64, uint32, uint16, uint8, and bool.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[33], line 11\u001b[0m\n\u001b[1;32m      8\u001b[0m y_train \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39marray(y_train)\n\u001b[1;32m      9\u001b[0m y_test \u001b[38;5;241m=\u001b[39m np\u001b[38;5;241m.\u001b[39marray(y_test)\n\u001b[0;32m---> 11\u001b[0m X_train_tensor \u001b[38;5;241m=\u001b[39m \u001b[43mtorch\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mtensor\u001b[49m\u001b[43m(\u001b[49m\u001b[43mX_train\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mdtype\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtorch\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfloat32\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m     12\u001b[0m X_test_tensor \u001b[38;5;241m=\u001b[39m torch\u001b[38;5;241m.\u001b[39mtensor(X_test, dtype\u001b[38;5;241m=\u001b[39mtorch\u001b[38;5;241m.\u001b[39mfloat32)\n\u001b[1;32m     13\u001b[0m y_train_tensor \u001b[38;5;241m=\u001b[39m torch\u001b[38;5;241m.\u001b[39mtensor(y_train, dtype\u001b[38;5;241m=\u001b[39mtorch\u001b[38;5;241m.\u001b[39mlong)\n",
      "\u001b[0;31mTypeError\u001b[0m: can't convert np.ndarray of type numpy.str_. The only supported types are: float64, float32, float16, complex64, complex128, int64, int32, int16, int8, uint64, uint32, uint16, uint8, and bool."
     ]
    }
   ],
   "source": [
    "features = np.array([np.array(fp) for fp in ddi_labels['concat_fingerprints']])\n",
    "labels = ddi_labels['labels']\n",
    "\n",
    "X_train, X_test, y_train, y_test = train_test_split(features, labels, test_size=0.2, random_state=42)\n",
    "X_train = np.array(X_train)\n",
    "X_test = np.array(X_test)\n",
    "\n",
    "y_train = np.array(y_train)\n",
    "y_test = np.array(y_test)\n",
    "\n",
    "X_train_tensor = torch.tensor(X_train, dtype=torch.float32)\n",
    "X_test_tensor = torch.tensor(X_test, dtype=torch.float32)\n",
    "y_train_tensor = torch.tensor(y_train, dtype=torch.long)\n",
    "y_test_tensor = torch.tensor(y_test, dtype=torch.long)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "import torch\n",
    "import torch.nn as nn\n",
    "import torch.optim as optim\n",
    "\n",
    "class DDI_NN(nn.Module):\n",
    "    def __init__(self, input_dim, hidden_dim, output_dim):\n",
    "        super(DDI_NN, self).__init__()\n",
    "        self.fc1 = nn.Linear(input_dim, hidden_dim)\n",
    "        self.relu = nn.ReLU()\n",
    "        self.fc2 = nn.Linear(hidden_dim, hidden_dim)\n",
    "        self.fc3 = nn.Linear(hidden_dim, output_dim)\n",
    "        \n",
    "    def forward(self, x):\n",
    "        x = self.fc1(x)\n",
    "        x = self.relu(x)\n",
    "        x = self.fc2(x)\n",
    "        x = self.relu(x)\n",
    "        x = self.fc3(x)\n",
    "        return x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
